Buprenorphine and naloxone (Zubsolv®). HTA ID: 22037

Assessment Status Rapid Review complete
HTA ID 22037
Drug Buprenorphine/Naloxone
Brand Zubsolv®
Indication As substitution treatment for opioid drug dependence, within a framework of medical, social and psychological treatment. The intention of the naloxone component is to deter intravenous misuse. Treatment is intended for use in adults and adolescents over 15 years of age who agreed to be treated for addiction.
Assessment Process
Rapid review commissioned 26/05/2022
Rapid review completed 21/06/2022
Rapid review outcome A full HTA is not recommended. The NCPE recommends that Zubsolv® be considered for reimbursement*.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.